A Study To Assess The Safety Of PF-05335810 In Hypercholesterolemic Subjects

A Phase I, Placebo-Controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Single, Ascending Doses Of PF-05335810 In Hypercholesterolemic Subjects, With One, Open-Label, Multiple Fixed Dosage Cohort

This study is to evaluate the safety, tolerability and immunogenicity of single, ascending or multiple fixed subcutaneous and intravenous administrations of PF 05335810 to hypercholesterolemic subjects when added on to a daily statin dose.

Inclusion Criteria:

• On stable daily doses of a statin for 45 days prior to receiving study treatment.
• Fasting LDL C equal or greater than 80 mg/dL at screening and visit approximately 1 week prior to randomization.

Exclusion Criteria:

• History of a cardiovascular or cerebrovascular event or procedure within one year of randomization.
• Poorly controlled type 1 or type 2 diabetes mellitus (defined as HbA1c >9%).